Fig. 4
Creation of a triple-omics integrated network in MNPs@SiO2(RITC)-treated BV2 cells. a The simply merged triple-omics network of 0.1 µg/µl MNPs@SiO2(RITC)-treated BV2 cells. Left group: transcriptome, Right group: proteome, Bottom group: metabolome. Down-regulated Fas was shared between the transcriptome and proteome in center. b PCA for triple omics against four categories of biological functions. Filled spots indicate items included in the simply merged triple-omics network. The translucent yellow circle indicates the location of the major dominant cluster. c The trimmed integrated network for four categories of biological functions. d The trimmed triple-omics network with addition of GSH. Factors directly related to GSH are highlighted in magenta. e Evaluation of viability in 0.1 µg/µl MNPs@SiO2(RITC)–treated BV2 cells co-treated with each of 19 drugs. AICAR: AMP-activated protein kinase activator; GW3965: nonsteroidal liver X receptor agonist; Nif: nifedipine, calcium channel blocker; Nim: nimodipine, voltage-dependent calcium channel blocker; A23187: calcium ionophore; dantrolene: calcium ion release inhibitor; DCA: dichloroacetate, pyruvate dehydrogenase activator; Rotenone: inhibitor of electron transport chain; citrate: a supplement for TCA cycle; SB216763: glycogen synthase kinase 3 inhibitor; Bay7082: inhibitor of inhibitory κB kinase; sodium salicylate: an NFκB inhibitor; SP: SP600125, C-JUN N-terminal kinase inhibitor; NMMA: L-NG-monomethyl-L-arginine, iNOS inhibitor; Che: chelerythrine, pan–protein kinase C inhibitor; apocynin: inhibitor of NADPH oxidase; 4-PBA: 4-phenylbutyrate, chemical chaperone; NAC: N-acetyl cysteine, antioxidant; GSH: glutathione, antioxidant. Data represent means ± SD of triplicate measurements. *p < 0.05 and **p < 0.01 according to one-way ANOVA as compared to control and MNPs@SiO2(RITC)-treated BV2 cells, respectively